StockData
CASI Pharmaceuticals, Inc. logo

CASI Pharmaceuticals, Inc. (CASIF) stock

CASIFOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026Score 1/30
$0.10+0.00 (0.00%)

Close on Oct 19, 2026Market cap –P/E –Yield –

CASI Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $6.31M, down 29.3% from the year before. The highest annual figure on record is $16.00M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.31M-29.3%
FY2024Dec 31, 2024$8.92M-9.6%
FY2023Dec 31, 2023$9.86M-38.4%
FY2022Dec 31, 2022$16.00M+10.9%
FY2021Dec 31, 2021$14.42M+25.7%
FY2020Dec 31, 2020$11.47M–

More CASI Pharmaceuticals figures

See a number that looks wrong?